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Abbreviations and glossary 
ADC Apparent diffusion 
coefficient 
BBB  Blood-brain-barrier 
BTSC  Brain tumour stem cell 
CT Tissue concentration of a 
tracer 
CBV  Cerebral blood volume 
CNR  Contrast-to-noise ratio 
CNS  Central nervous system 
CNS-1  Rat astrocytoma cell line 
CSC  Cancer stem cell 
CSF  Cerebral spinal fluid 
D0 Fractional blood volume, 
i.e. fraction of perfused 
blood volume [mM] (Su’s 
model) 
D1 Describes the permeability 
between the vessels and 
tissue, is proportional to the 
transfer constant between 
vessels and tissue [mM 
min-1] (Su’s model) 
DCE-MRI Dynamic contrast enhanced 
MRI 
DSC-MRI Dynamic susceptibility 
contrast MRI 
DWI  Diffusion weighted 
imaging 
EES Extravascular extracellular 
space 
ECF  Extracellular fluid 
FDA US Food and Drug 
Administration 
FLAIR Fluid attenuated inversion 
recovery, MRI sequence 
Gd  Gadolinium 
GE Gradient echo, MRI 
sequence 
GBM  Glioblastoma multiforme 
GRID Gadolinium Rhodamine 
Dextran 
ICP-MS Inductively coupled plasma 
– mass spectrometry 
IR Inversion recovery, MR 
sequence 
i.v.  Intravenous  
K2 Rate constant between EES 
and blood plasma [min-1] 
(Su’s model) 
Ktrans Transfer rate, volume 
transfer constant between 
blood plasma and EES, 
[min-1] (Tofts’ model) 
kep Rate constant, rate constant 
between EES and blood 
plasma [min-1] (Tofts’ 
model) 
M Molar 
M Bulk magnetisation vector 
M0 Magnitude of 
magnetisation vector prior 
to excitation pulse 
Mx, My, Mz Directional components of 
M 
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imaging 
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resonance 
NSC  Neural stem cell 
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r Relaxivity of the contrast 
agent [mM-1 s-1] 
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SPIO Superparamagnetic iron-
oxide particles 
TE  Echo time 
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time constant [s] 
T2 Transverse relaxation time 
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modified genetically to 
express NG2 
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to U251-NG2 
USPIO Ultrasmall 
superparamagnetic iron-
oxide particles 
ve EES, volume of 
extravascular extracellular 
space  per unit volume of 
tissue, i.e. volume fraction 
of EES or leakage space 
(Tofts’ model). 
Voxel  Volume element 
WHO  World Health Organization 
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Introduction 
Preface 
Magnetic resonance imaging (MRI) has emerged as a powerful and robust tool in the 
identification and study of diseases in the central nervous system (CNS) since it was first 
introduced in 1970s. MRI is in many cases the method of choice in diagnosis and treatment 
evaluation, due to its unique soft tissue contrast, high spatial resolution and physiological 
sensitivity. Also, as it is non-invasive and utilises non-ionising radiation, MRI is considered 
as a safe and reliable imaging method (2).  
Magnetic resonance is based on the magnetic properties of atomic nuclei, and this 
phenomenon was first described in 1938 (3). A few years later, Felix Bloch and Edward 
Purcell independently reported detections of magnetic resonance in bulk matter (4-6). In 
1971, the American physician Raymond Damian stated that nuclear magnetic resonance 
(NMR) could distinguish between cancerous and healthy tissue, and for the first time a clear 
biological application of NMR was shown (7). The first MR image was generated in 1972 by 
Paul Lauterbur, and reported in Nature in 1973 (8) after first being rejected by the same 
journal due to lack of wide significance. Improvements of image formation by Peter 
Mansfield in 1976 greatly improved the feasibility of MRI. In 1977, the first human 
magnetic resonance scanner was developed by Damadian’s FONAR Corporation (2). The 
US Food and Drug Administration (FDA) approved MRI scanners for clinical use in 1985 
(2). The first MRI scanner in Norway was installed at Stavanger University Hospital in 
1986. Over the years, the number of MRI scanners has exploded, and are extensively used 
both in clinical and research settings. In 2003, Peter Mansfield and Paul Lauterbur were 
awarded with the Nobel Prize (Medicine/Physiology) for applying the fundamental 
discoveries of NMR to medical imaging.  
1.1  Basic principles of MRI 
To introduce the basic concepts and terminology, the basic principles of magnetic resonance 
imaging are briefly described below. For a thorough description of the physical principles, 
readers should be referred to standard MRI textbooks, e.g. (9) 
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1.1.1 Nuclear spin 
For MRI to provide tomographic images a strong magnetic field is required combined with 
application of smaller local fields (gradients) and electromagnetic transmit- and receive-
coils. The technique utilizes electromagnetic properties of specific nuclei naturally abundant 
in body tissues. So far the hydrogen nucleus, H+ (which is a proton), is the most interesting 
nucleus because of its high abundance (about 2/3 of body weight is water), and because it 
gives the strongest signal. The proton is a charged particle with spin, and exhibits the 
electromagnetic properties of a dipole magnet. In the absence of an external magnetic field, 
the directions of the protons are random and thus no net magnetization is produced. When 
body tissue is placed in an external magnetic field B0, the direction of the protons is either 
parallel or anti-parallel with B0. They not only rotate about their own axis but also precess 
about the axis of the external magnetic field with a specific rate. This can be expressed by 
the Larmor equation: 
ω0 = γB0   
where ω0 is the angular precessional frequency, γ is the gyromagnetic ratio specific for the 
nuclei, and B0 is the strength of the external magnetic field. The gyromagnetic ratio is a 
proportionality constant dependent on the kind of nucleus, where the hydrogen nucleus has 
the highest gyromagnetic ratio. A net magnetization M0 is produced in the same direction as 
B0 because of an excess of parallel protons compared to anti-parallel protons. The direction 
of B0 and M0 is defined as the z-axis in a 3-dimensional coordinate system.  
An electromagnetic wave, a pulse of radiofrequency (RF) energy, with the same 
frequency as the precessing protons, is then applied to the body tissue. This generates a 
resonance condition which excites the protons. As a consequence, the M0 vector along the z-
axis is flipped into the x-y plane. There is now a magnetization vector, Mxy, in the x-y plane 
with an initial value equal to M0, precessing around the axis of the external magnetic field. A 
receiver coil placed in the xy plane measures the net magnetization as the oscillating nature 
of Mxy induces a current in the coil. This measured signal, which is referred to as the free 
induction decay (FID), will reduce or decay due to proton relaxation processes which are 
further described below. The time between each successive excitation pulse is termed the 
repetition time, TR. For each RF pulse, the MR signal is sampled after a given delay (~ms), 
which is referred to as the echo time, TE. The MR signal may be manipulated or sampled in 
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many different ways by multiple combinations of pulses and sampling processes, referred to 
as pulse sequences.  
1.1.2 Intrinsic contrast mechanisms  
The versatility of MRI is achieved by exploiting contrast mechanisms to generate images. 
The contrast mechanisms in MR imaging are based on tissue-specific parameters, utilized 
with appropriate pulse sequence choice, sometimes with the application of a contrast agent. 
Only the intrinsic and static contrast mechanisms T1, T2/T2* and proton density (PD) will 
be presented below. 
T1 relaxation time 
The protons are in a state of high energy when excited and when the RF pulse is turned off, 
they return to their equilibrium state which is by definition the lowest energy state of the two 
possible. The protons release all their excess energy and realign with the axis of the external 
magnetic field B0. Hence, the Mz vector will grow with a time constant T1, which is called 
the longitudinal relaxation time or the spin-lattice relaxation time. T1 is tissue dependent and 
is one of the main contrast parameters in MRI. The chemical environment the protons 
experience in the tissue determines the rate of the relaxation of the protons (T1 relaxation 
rate, R1, is defined as 1/T1). Free water molecules have a longer relaxation time than bound 
or structured water molecules, resulting in different T1 values for the different types of 
tissue. Fat and free water, such as the cerebrospinal fluid (CSF), are the two contrary tissues 
when it comes to T1 relaxation rate. Strong tissue contrast on T1-weighted images is 
obtained by choosing an optimal TR that maximises the contrast between tissues with a 
slightly different T1 value (Figure 1). To obtain images with a strong T1 contrast, a short TR 
and a short TE is normally chosen. In addition to being tissue-specific, the T1 relaxation rate 
is also dependent on field strength, with shorter T1 at lower field strengths. Thus, the TR 
must be optimised for the field strength applied. 
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Figure 1: T1 contrast  
 
T2 relaxation time 
One of the other main contrast parameters is the T2 relaxation time. When the RF pulse is 
applied to the system and the longitudinal magnetic vector is flipped into the xy plane, all 
the rotating protons are in the same phase and the net magnetization Mxy has its maximum 
value. Immediately after the RF pulse is turned off the protons will start to dephase and Mxy 
starts to decrease with a time constant T2. This effect is primarily related to the intrinsic 
field variations due to adjacent protons, and is therefore referred to as spin-spin relaxation 
time, or transverse relaxation time, since it takes place in the transverse (xy) plane. The 
effect of the spin-spin interaction depends on the proximity of the protons to each other. In 
water, the protons are separated more widely than in solid tissue and thus the dephasing 
effect is not that prominent in water as in solid tissue. T2-weighting of an image is 
emphasised by using long TR and long TE (Figure 2). The second cause of dephasing is due 
to external magnetic field in-homogeneities. This makes the protons at different locations 
precessing at different frequencies because each proton is exposed to a slightly different 
external magnetic field strength. When this cause of dephasing is emphasised, the image is 
T2*-weighted.  
Figure 2: T2 contrast  
 
The figure shows a T1-weighted 
image acquired on a 1.5 T system.  
The graphs to the left illustrate 
the tissue specific speed of T1 
(recovery of Mz) and T2 
relaxation (decrease of Mxy), and 
the optimum TR and TE for gray 
and white matter differentiation 
on T1-weighted images. Adapted 
from (1). 
The figure shows a T2-weighted 
image acquired on a 1.5 T system.  
The graphs to the left illustrate the 
tissue specific speed of T1 
(recovery of Mz) and T2 
relaxation (decrease of Mxy), and 
the optimum TR and TE for gray 
and white matter differentiation on 
T2-weighted images. Adapted 
from (1). 
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Proton density 
One of the simplest forms of MR contrast is PD imaging. The net magnetisation of each 
voxel is composed of individual spins within that voxel. As the name implies, tissue contrast 
is provided based on the sheer number of protons within a voxel, which differs across tissue 
types. To maximise the proton density weighting of an image, the effects of T1 and T2 are 
minimised by using long TR and short TE. 
1.2 MR contrast agents in neuroimaging 
In the early days of MRI, it was believed that there was no need for external contrast agents 
in MR examinations. However, in the late eighties, the development of MR contrast agents 
started in order to improve the definition of the internal structures and function of the body, 
thereby making the method even more sensitive and the diagnosis more specific (10). MRI is 
very sensitive to the effects of the contrast agent, allowing a significant reduction in contrast 
agent dose compared to what is used in conventional X-ray imaging modalities. Contrary to 
radiographic contrast agents, which change the local density and thus create a direct change 
of the contrast in the image, MR contrast agents induce a change in the local magnetisation 
in its surrounding tissue. Hence they have an indirect effect on the image contrast. It is the 
magnetic properties of the contrast agent that is explored by MRI, and contrast agents affect 
hydrogen magnetisation in two primary ways i) through direct relaxivity effects (changing 
T1 and T2 relaxation rates of the tissue) or ii) through indirect susceptibility effects (11). 
The contrast agent’s ability to induce signal changes through direct interactions with protons 
in surrounding tissue is described by its relaxivity. The increase in relaxation rate (R1 = 1/T1 
or R2 = 1/T2) per unit concentration of tracer (i.e. contrast agent) is the relaxivity r1,2= (R1,2b-
R1,2a)/ΔC, where r1,2 is measured in mM-1 s-1. Susceptibility relaxation is caused by 
differences between the paramagnetic contrast and the surrounding tissue protons. This 
contrast mechanism influences relaxation effects in tissue at longer distances than dipolar 
relaxation. Due to its sensitivity to field inhomogeneities, it is primarily the transverse 
relaxation rate that is affected by susceptibility relaxation (12). 
Most contrast agents can be used to produce both effects, but in general one effect 
dominates, depending on the concentration of the contrast agent, MR imaging techniques, 
and tissue distribution properties. Contrast agents are often grouped into paramagnetic or 
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superparamagnetic contrast agents based on their magnetic properties. At present, 
paramagnetic contrast agents are the most frequently used and have become an integrated 
part of the daily practise of MRI (13, 14). Contrast agents are also termed positive and 
negative contrast agents, due their dominating effect on the signal on the MR image (i.e. 
signal enhancing due to dominating T1 effect or signal attenuating due to dominating T2 
effect, respectively). Furthermore, MR contrast agents can be grouped according to their 
biological distribution; extracellular fluid-contrast agents (ECF-agents), blood-pool agents or 
targeted/tissue-specific agents. Low-molecular contrast agents are classified as ECF-agents 
as they rapidly equilibrate between the intravascular and extravascular spaces. However, the 
brain is different from the body as the contrast agent is retained intravascularly in the case of 
an intact blood-brain-barrier (BBB). Contrast agents for cellular MR imaging are further 
described in section 1.7.1. 
1.2.1 Paramagnetic contrast agents 
Gadolinium (Gd) is a lanthanide metal with paramagnetic properties and is the most 
commonly used compound in MR contrast agents. As Gd is toxic, the compound is chelated, 
and Gd-based contrast agents are regarded as safe and are well tolerated when injected 
intravenously (i.v.) (15). First generation, or low-molecular weight Gd-based contrast agents 
(~500 Da), such as Gd-DTPA (Magnevist, Schering/Berlex), Gd-DTPA-BMA (Omniscan, 
Amersham Health), Gd-DO3A-butrol (Gadovist, Schering) and GdHP-DO3A (ProHance, 
Bracco) share similar distribution and enhancement properties at lower field strengths (16) 
(r1 ranging between and 3.4-3.8 mM-1 s-1 at 1.0 T). The typical relaxivity dependence on the 
magnetic field for Gd-compounds is a maximum followed by a decline as the field strength 
increases. The Gd-based agents are regarded as positive contrast agents as their predominant 
effect is shortening of the T1 relaxation time, seen as hyperintensity on the MR image.   
In the case of highly malignant brain tumours, the contrast agent leaks out into the 
tumour tissue due to disruption of the BBB, and the regions with contrast enhancement may 
correspond well with the solid tumour mass. However, Gd-enhancement is relatively non-
specific. For instance, it may be difficult to differentiate between radiation necrosis and 
recurrent tumour after radiation therapy (17). More innovative developments in MR contrast 
agent design have led to the emergence of new second generation Gd-based compounds 
which differ from currently available agents in possessing markedly increased in vivo T1 
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relaxivity. Generally, second generation contrast agents also have a higher molecular weight 
than the first generation Gd-based agents, and are regarded as blood-pool contrast agents. 
The use of high relaxivity agents in diagnosis of brain tumours may improve detection and 
delineation of the tumours, hence improving the sensitivity and differential diagnostic 
processes (16). Macromolecular contrast agents may also give a better correlation between 
histologic tumour grade and permeability parameters assessed by dynamic contrast enhanced 
(DCE) imaging as demonstrated in animal models using albumin-Gd-DTPA-30 (18). 
Gadomer (Schering AG, Germany) has also proved to be a promising contrast agent for early 
detection of treatment effects or residual disease in tumours (19-21) and is suggested as an 
important tool in future clinical settings (22). The role of MR imaging in the diagnosis and 
follow-up of brain tumours is further described in section 1.6. 
1.2.2 Superparamagnetic contrast agents 
Iron-oxide or dysprosium based contrast agents are regarded as superparamagnetic contrast 
agents. They are often termed negative contrast agents as their predominant effect is signal 
attenuation due to shortening of the T2 relaxation time or susceptibility effect. 
Superparamagnetic iron-oxide (SPIO) or ultrasmall SPIO (USPIO) are the most commonly 
used negative contrast agents and the T2 and T1 relaxivity of a typical (U)SPIO is 
substantially larger than the relaxivity of paramagnetic compounds (23). The observed 
effects on signal intensity depend on several factors, including particle composition, particle 
size, and concentration within a voxel. Most (U)SPIOs are classified as blood-pool contrast 
agents and do not play a significant role in neuroimaging and brain tumour diagnosis yet. 
However, the potential of using USPIOs in this regard has been investigated. Enochs and co-
workers observed that compared to Gd-chelates, long circulation SPIOs can provide 
prolonged delineation of the margins of human brain tumours on MR images, which has 
implications for the targeting of diagnostic biopsies and the planning of surgical resections 
(24). Others have reported that USPIOs can not replace Gd-based contrast agents in the 
diagnosis of brain tumours as the tumour volumes visualised on USPIO contrast enhanced 
T1-weighted images do not correlate with contrast enhancement with Gd-based agents (17). 
In a study where the tumour delineation was evaluated by T2 pulse sequences, demarcation 
of the tumour border was difficult due to a blooming effect, but USPIOs seemed to enhance 
delineation of neovascularisation (17). Zimmer and co-workers reported that phagocytosis of 
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monocrystalline iron-oxide particles (MION) by glioma cells has been observed in a rat 
glioma model, which permitted determination of tumour margins (25). The role of (U)SPIOs 
in cellular MR imaging is described in 1.7.1. 
1.3 Primary brain tumours  
Gliomas are tumours derived from glial cells (i.e. astrocytic, oligodendrocytic, ependymal or 
mixed origin). Astrocytoma is the most frequently observed and accounts for approximately 
65% of primary brain tumours. The most malignant of these, is the glioblastoma multiforme 
(GBM). There are regional variances in the tumour incidence, with a higher frequency in 
Europe, Australia and North-America (26). Within the Western world there are usually 
around 6-11 new cases of primary intracranial tumours reported per 100.000 capita in men 
and 4-11 in women, with an increasing frequency with increasing age (26). There has been a 
growing number of gliomas reported per year in industrialised countries, which has been 
attributed to the development of high-resolution neuroimaging techniques such as computer 
assisted tomography (CT) and MRI. In the Nordic countries, the increase in incidence was 
confined to the late 1970s, which coincided with the introduction of improved diagnostic 
methods (27). 
1.3.1 WHO classification 
In keeping with the degree of aggressiveness, gliomas are divided into four grades according 
to their biological behaviour. As different gliomas show a heterogeneous histological 
appearance, the final classification includes both histological features and degree of 
malignancy or anaplasia. At present, the classification system of the World Health 
Organization (WHO) is used. Gliomas of astrocytic origin (astrocytomas) are classified into 
pilocytic astrocytoma (Grade I), low-grade astrocytoma (Grade II), anaplastic astrocytoma 
(Grade III), and GBM (Grade IV) (28). The significant indicators of anaplasia include 
nuclear i) atypia, ii) brisk mitotic activity, iii) increased cellularity, iv) vascular proliferation, 
and v) necrosis (see Table 1.3.1). Two distinct types of GBMs are recognised, based on their 
clinical history. Primary GBMs are characterised by a very rapid development of clinical 
symptoms, where approximately 50 % of the patients have a history of less than six months, 
whereas secondary GBMs evolve from progression of low-grade astrocytoma and anaplastic 
 17
astrocytoma in the course of several years (mean 4-5 years) (29). Primary GBMs tend to 
develop in older patients (mean age 50-55 years), while secondary GBMs have a peak at a 
lower age (i.e. 40 years) (29).  
Table 1: The WHO classification system of astrocytomas 
WHO grade WHO designation Histological criteria 
I Pilocytic astrocytoma None of the below criteria 
II Astrocytoma (low-grade diffuse) Nuclear atypia 
III Anaplastic astrocytoma Nuclear atypia and mitotic activity 
IV Glioblastoma multiforme Nuclear atypia, mitosis, endothelial 
proliferation and/or necrosis 
 
Neurological symptoms from glioma development depend mainly on the location of the 
tumour within the brain. However, each glioma subtype has a specific prognosis that dictates 
the clinical management. The length of the patient’s clinical history and the chance of a 
long, recurrence-free survival are closely related to the histopathological characteristics of 
the neoplasm. Despite advances in surgical and clinical neuro-oncology, mortality rates are 
still high and GBM patients have a mean survival of less than a year after diagnosis. Also, 
higher age is the strongest prognostic factor of poor survival of these patients (30).  
1.3.2 The cellular origin of gliomas 
The somatic mutation hypothesis 
The predominant theory about the origin of gliomas is that these tumours develop from 
somatic mutations in differentiated mature astrocytes or oligodendrocytes, which 
subsequently undergo series of transformation steps to a less differentiated phenotype (31). 
However, the somatic mutation hypothesis does not explain the perplexing paradox that 
whilst normal glial cells tend to be morphologically homogeneous, malignant gliomas, 
which are presumed to be of clonal lineage, display striking cellular heterogeneity. 
Furthermore, the prognostic power of the WHO classification nomenclature relies mostly on 
the tumour architectural features (28) (Table 1). There exists an inconsistency when lower 
grade gliomas, exhibiting endothelial proliferation, are not classified as GBMs. Moreover, 
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not only are gliomas heterogeneous in their cellular morphology, but individuals with 
malignant gliomas show marked variations in response to current treatment modalities. 
The cancer stem cell hypothesis 
An alternative hypothesis posits that subpopulations of cancer cells within tumours reflect 
the developmental hierarchy of the normal tissue from which the tumour arose. This model 
suggests that tumours are driven and maintained by a small subpopulation of cells that have 
the capacity to self-renew and to generate a more differentiated progeny, which make up the 
tumour mass (32, 33). This cell population has been termed cancer stem cells (CSC), 
tumourigenic cancer cells, or tumour-initiating cells. Brain tumours could thus arise from 
transformed neuroepithelial stem cells or glia precursor cells, which show capabilities of 
self-renewal by asymmetric cell division. This may lead to a variety of brain tumour types 
that harbour cell types that show different stages of cellular differentiation. In vitro analyses 
of brain tumour cells sorted for CD133 expression (cell surface protein which is a marker for 
stem cells such as NSCs), indicated that the capacity of self-renewal and proliferation 
exclusively resides in the minority of CD133+ cell fraction, which may imply that this 
surface protein may be a new cell surface marker for brain tumour stem cells (BTSC) (34). 
In vivo experiments conducted by the same group showed that only the CD133+ cells were 
capable of tumour initiation in the NOD-SCID (non-obese diabetic, severe combined 
immunodeficient) mouse brain (35). The identification of brain tumour initiating cells may 
provide insights into human brain tumour pathogenesis, giving strong support to the CSC 
hypothesis as the basis for many solid tumours, and establishes a previously un-identified 
cellular target for more effective cancer therapies (32, 36). 
1.3.3 Brain tumour biology 
To describe the biological properties of brain tumours in detail is beyond the scope this 
thesis. However, some key features such as invasion and angiogenesis will be presented in 
the following sections. 
Diffuse invasion 
Primary brain tumours are characterised by a diffuse local invasion of migrating tumour 
cells that leads to a poor demarcation of the neoplasm. Invasion of tumour cells into normal 
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tissue is thought to be a multi-factorial process involving changes in cell morphology, cell-
cell and cell-extracellular matrix (ECM) adhesion interactions, and remodelling of the 
extracellular space by proteases (37, 38). Migratory tumour cells exhibit a different 
phenotype from non-migrating tumour cells as they may show reduced proliferation and loss 
of normal cell regulatory mechanisms (38). These migrating cells represent a therapeutic 
challenge as they give rise to recurrent tumours following surgical and chemo- and 
radiotherapeutic interventions as further described in section 1.4. 
Angiogenesis 
Angiogenesis plays a key role in the pathogenesis of tumours and is essential for tumour 
growth (31). Without angiogenesis, most solid tumours can not grow beyond 1-2 mm in 
diameter. Normally there is a fine balance between stimulators and inhibitors of 
angiogenesis but in malignant tumours, pro-angiogenic factors prevail, where vascular 
endothelial growth factor (VEGF) is among one of the key stimulators of endothelial cell 
proliferation (31, 39). The tumour tissue can recruit its blood supply through different 
pathways such as i) vascular sprouting from pre-existing host vessels in the surrounding 
normal tissues, ii) cooption of pre-existing host vessels, i.e. the tumour cells survive under 
the existing host vasculature, and iii) recruitment of circulating bone-marrow derived 
endothelial cells that develop new blood vessels within the tumour (39, 40). Angiogenesis is 
usually linked to tumour aggressiveness. For gliomas there is a clear increase in 
angiogenesis from low- to high-grade tumours (41). 
1.4 Conventional and experimental treatment strategies  
The current standard treatment approach for patients with high-grade gliomas consists of 
surgical resection, preferably a gross-total resection of the solid tumour mass, followed by 
radiotherapy and/or chemotherapy (42, 43). In general, the effect of treatment on the overall 
prognosis has been limited, and the expected postoperative survival for GBM patients is less 
than a year (30). GBMs are difficult to treat and represent a special treatment challenge due 
to the following characteristics (44): i) invasive growth and spread of malignant cells into 
brain parenchyma, ii) intrinsic resistance to conventional therapy, iii) the localisation of 
tumours may preclude surgical resection, iv) limited capacity of the brain to repair itself, v) 
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variably disrupted BBB complicating effective drug-delivery, vi) tumour capillary leakage 
with resulting peritumoural oedema and intracranial hypertension, and vii) neurotoxicity as a 
result of aggressive treatment procedures. At present, there is a need for new and more 
effective therapeutic modalities for malignant brain tumours, and a better understanding of 
the biological properties of the tumour is essential. It may be that recent advances in 
neuroimaging will give some answers regarding biological parameters related to a treatment 
response. With a continued improvement in treatment and imaging techniques, there is a 
hope that GBM may be a controllable disease. Research in gene therapy, antiangiogenic 
therapy, and immunotherapies holds some promise (45) but to address these issues in detail 
is beyond the scope of this thesis.  
1.4.1  Neural stem cells as a potential treatment modality 
The discovery and characterisation of a pool of neural stem cells (NSC) that persists into 
adulthood and retain the capacity to self-renew and differentiate, has provided new avenues 
for researchers to investigate mechanisms of brain tumour formation and treatment response. 
To date, the neuro-biological findings using stem cells have been applied i) towards a better 
classification of tumours to hopefully improve prognostics (46) and ii) as a potential vehicle 
to improve delivery of therapeutic agents into brain tumours (47-50). Due to the inherent 
pluripotency of NSCs, another potential role of such cells may be to repair tissue damage 
caused by the brain tumours in situ and the neurological impairment that is frequently 
associated with traditional cancer treatment approaches (51, 52).  
The main characteristic of NSCs that make them attractive vehicles for targeted 
delivery, is their tropism towards neoplasms. Aboody and colleagues where the first to 
describe that modified exogenous NSCs injected at various sites (both ipsilateral and 
contralateral hemisphere to the brain tumour, into the cerebral ventricles, and into systemic 
circulation) had the capability to migrate over long distances towards the glioma. They also 
reported that NSCs positioned themselves juxtaposed to glioma cells migrating away from 
the main tumour mass (47), indicating that NSCs may mimic the migratory pattern of 
infiltrating glioma cells (48). This can be exploited to target minute brain metastases and 
infiltrating malignant satellites after tumour resection (53). NSCs also have the potential to 
integrate into the host brain without disrupting normal tissue function (53). Exogenous NSCs 
may be clonally expanded in tissue culture, providing a renewable supply of material for 
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transplantation. As they can be propagated for long periods, it also makes them amenable 
genetic manipulation. Several groups have in recent years reported promising results using 
NSC-based gene therapy in animal models of high-grade gliomas and different therapeutic 
strategies have been developed, resulting in reduced tumour growth (47, 49, 54-56) and 
extended survival (48, 57, 58). An intrinsic tumour-inhibitory effect of neural stem cells has 
also been reported when NSCs were co-inoculated with glioma cells (59) or grafted into 
established gliomas (48). NSCs may represent a vehicle for the delivery of genes and 
proteins to brain tumours and the use of such cells also represent a targeted delivery 
approach for substances that require distribution throughout the brain.  
1.4.2  NG2 progenitor cells as a potential target for brain tumour therapy  
Neuron-glial 2 (NG2)-expressing cells are the largest proliferating cell population in the 
adult CNS (60). NG2 is a highly conserved chondroitin sulfate transmembrane proteoglycan 
that is expressed on oligodendrocyte precursor cells of the developing and mature CNS (61). 
The function of NG2-expressing cells is largely unknown but the cells are activated to 
proliferate following different forms of CNS damage, such as mechanical injury, 
excitotoxicity, viral infections and tumour development (62). Chekenya and co-workers have 
previously reported increased NG2 expression in 13 out of 18 human GBMs. NG2 was 
found to be expressed on both the tumour cells and by the associated vasculature (63). NG2 
has also been shown to increase tumour cell proliferation in vitro, and to promote 
angiogenesis in vivo, which predisposes animals to poorer survival outcomes by binding 
angiostatin (64, 65). High NG2 expression also coincides with resistance to chemotherapy, 
where it may be a novel regulator of chemoresistance (Chekenya et al, submitted). Thus, 
NG2 plays a major role in tumour-stroma activation through alterations in cellular adhesion, 
migration, proliferation, and vascular morphogenesis, and increased NG2 expression 
correlates with an aggressive disease course (63). NG2 is expressed on the cell surface, and 
due to its putative role in tumour-host interactions, it is suggested as an attractive candidate 
for targeted brain tumour therapy (66-69). 
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1.5 Experimental glioma models 
There is a considerable need for appropriate animal models in experimental neuro-oncology 
(70). By using valid model systems, the genetic events leading to oncogenesis can be 
studied, possible targets for tumour therapy can be identified, and knowledge about tumour 
angiogenesis and invasion can be provided (71). Another rationale for using in vivo animal 
models is to assess the efficacy of innovative treatment approaches. Rat brain tumour models 
have extensively been used since the mid 1970’s (70). Initially, the tumours were induced by 
using various neurotrophic carcinogens, later cell lines were generated from human GBMs 
and then transplanted into the CNS of immunodeficient rats (71). The advantage of cell line-
based models is high efficacy with reproducible growth rate, survival time, and tumour 
location. Moreover, immortalised cell lines are readily expanded in vitro, allowing almost 
unlimited amounts of tumour material for experimental use. A major disadvantage of using 
cell line-based systems is genetic and phenotypic deviations caused by the tissue culture 
environment. To circumvent this problem GBM models have been initiated by short term 
cultures of the patient’s biopsy material in the form of multicellular spheroids without 
previous passaging in monolayers (72). When transplanted into the rat brain, tumours will 
develop that show several biological features reflecting the original tumours in situ such as 
extensive cell invasion  and angiogenesis (72, 73). Another attractive approach for studying 
brain tumours and treatment modalities is the use of transgenic animals but such models will 
not be addressed in the current work.   
1.6 MR imaging of brain tumours 
The crucial role of neuroimaging in neuro-oncology include refinement of pre-operative 
differential diagnosis, precise anatomical localisation, detection of response to treatment and 
tumour progression, and recognition of treatment related side-effects (74). Cranial CT and 
MRI are widely used for primary diagnosis of brain tumours (75), but MRI is the method 
that provides the most comprehensive imaging information needed for patient diagnosis and 
treatment evaluation, due to its high spatial resolution and high tissue contrast (75, 76).  
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1.6.1 Conventional MR imaging 
The diagnosis of brain tumours by MRI is usually based on basic pre-contrast T1-weighted 
and T2-weighted images and post-contrast T1-weighted images in one or two orthogonal 
directions (76). Standard T1- and T2-weighted sequences detect brain tumours with high 
sensitivity (75). The recognition of neoplasms is mainly based on the mass effect and signal 
alterations caused by pathological processes due to tumour formation and progression. Most 
tumours appear as hypointense on pre-contrast T1-weighted images (Figure 3 A) and 
hyperintense on T2-weighted images (Figure 4 B) due to elongation of T1 and T2 relaxation 
times caused by the presence of vasogenic oedema and/or tumour infiltration (75). On PD-
weighted images, brain tumours appear as hyperintense (75) (Figure 4 A). I.v. injections of a 
positive contrast agent will in cases of a disrupted BBB cause a signal enhancement on T1-
weighted images due to leakage of the contrast agent from blood vessels into tumour tissue 
(Figure 3 B-D). Secondary effects of a tumour, such as necrosis, haemorrhage, and 
formation of cysts, modulate the appearance of tumours on MR images, which may make 
them more conspicuous but at the same time more easily to be mistaken for non-neoplastic 
lesions (76).  
Figure 3: T1-weighted MR images of a patient with GBM 
 
The figure shows T1-weighted MR images 
of a 53 year old male patient with GBM, 
acquired with a 3T GE Signa Excite 
(Haukeland University Hospital, images 
kindly provided by Turid Randa and Roger 
Barndon). A) a pre-contrast axial slice 
showing a hypointense region in the 
frontal lobe. B) corresponding slice 
acquired after i.v. injection of a Gd-based 
contrast agent, showing a non-enhancing 
central necrosis surrounded by a ring 
enhancement. C) and D) coronal and 
sagittal slices of the same patient, 
respectively. 
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These conventional MR imaging techniques are not sufficient for the grading and 
specification of brain tumours but there are correlations between the appearance on MR 
images and the histological features of gliomas, as a set of various MRI acquisition 
parameters give a characteristic pattern of each tumour depending on tumour type and grade 
(74, 75). Low-grade diffuse astrocytomas (WHO grade II) most often appear as homogenous 
hyperintense on T2-weighted images and peritumoural oedema is usually not present. T1 
post-contrast images do not give any evidence of abnormal contrast enhancement, which 
indicates absence of tumour angiogenesis in these tumours. WHO grade III gliomas 
(anaplastic astrocytomas) show typically nodular areas of contrast enhancement, moderate 
expansion of affected brain regions due to increased cellularity, and in some cases vasogenic 
oedema surrounding the main tumour mass (74). GBMs (WHO grade IV) show signs of 
widespread peritumoural oedema and tumour infiltration, appearing as strongly hyperintense 
areas on T2-weighted images. A distinct mass effect which may cause a mid-line shift 
visible in all imaging sequences and a heterogeneous signal enhancement on T1 post-
contrast images are other typical GBM imaging characteristics. Areas of necrosis appear as 
hypointense on T1 post-contrast images and if cystic, strongly hyperintense on T2-weighted 
images. The presence and degree of tumour necrosis visible on MR images correlates with 
clinical outcome and survival of patients with GBM (77).  
 
Figure 4: PD-weighted, T2-weighted and T2 FLAIR images of a patient with GBM 
 
The figure shows MR images of the same patient as in figure 3 (images acquired at the same time-point). A) 
PD-weighted image with a modest hyperintense region, B) T2-weighted image where the tumour and the 
peritumoural oedema appear as hyperintense, C) the tumour region appear as hyperintense on the T2-
weighted FLAIR image. The MR images are kindly provided by Turid Randa and Roger Bandon at Haukeland 
University Hospital. 
Another MR imaging technique, suggested as a valuable tool for tumour diagnosis and 
grading, is the fluid attenuated inversion recovery (FLAIR) sequence (78) (Figure 2 C). The 
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FLAIR sequence is either T1- or T2-weighted, with an inversion recovery which eliminates 
the signal from cerebral spinal fluid (CSF). T2-weighted FLAIR is extensively used for 
diagnosis of for example multiple sclerosis. In the case of low-grade astrocytomas, lesions 
have been demonstrated with greater conspicuity than with conventional T2-weighted 
sequences (79). T2-weighted FLAIR can also be used to differentiate the tumour mass from 
oedema in cases where the solid tumour induces a strong hyperintensity in T2-weighted 
images (78). Recent studies have reported that post-contrast FLAIR sequences due to a 
marked T1 effect, may improve the depiction of brain tumours by a distinct contrast 
enhancement, resulting in higher tumor-to-background contrast ratio compared with standard 
imaging techniques (80, 81).  
1.6.2 Functional MR imaging of brain tumours 
Advances in MRI allow studies of physiological processes in time and analysis of tumour 
tissue properties such as perfusion, angiogenesis and water mobility within the tissue. 
Morphologic imaging may not always meet the need for characterising biological processes, 
and the above mentioned parameters may serve as surrogate markers for these (82). 
Functional MRI methods such as dynamic contrast enhanced T1-weighted imaging (DCE-
MRI), dynamic susceptibility contrast imaging (DSC-MRI), and diffusion weighted imaging 
(DWI) are presented below. 
DCE-MRI and DSC-MRI 
Quantification of the tumor angiogenesis status might serve both as a prognostic index for 
the specific tumour examined and as a tool for monitoring effects of antiangiogenic or 
antivascular treatment (83-86). To assess angiogenesis, DCE-MRI or DSC-MRI can be 
applied to quantitatively characterize certain tumor microvascular properties, including 
richness of vascular supply and vascular endothelial leakiness or permeability. 
DCE-MRI is performed in order to achieve non-invasive assessment of vascular 
permeability. After baseline images are acquired, the contrast agent is injected i.v. and the 
time course of the tracer is followed by dynamic T1-weighted imaging. T1-weighted kinetic 
enhancement curves have three distinct phases; the up-slope, maximum enhancement and 
the wash-out. It is generally recognised that the up-slope gradient in tumours is highly 
dependent on tissue perfusion and permeability. Maximum enhancement is related to the 
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total uptake of the contrast medium in the extravascular extracellular space (EES) and the 
wash-out rate is associated with the decrease of tissue contrast agent concentration and is 
related to vascular permeability (83). Depending on the molecular size of the contrast agent 
used, the acquisition time needed to follow the course of the tracer varies from 3-4 to 30 
minutes with a typical temporal resolution of 10-30 seconds.  
Quantification of microvascular permeability parameters is done by implementing 
pharmacokinetic models that estimates the permeability of the tracer as a surrogate marker. 
Three major models have been reported for leakage studies (87-89). The methodologies for 
permeability quantification have been reviewed and a consensus has been reached (90). 
Common parameters to describe permeability are Ktrans and kep, where the former is related 
to the product of vessel surface and vessel permeability, and kep reflects transfer from the 
EES to the plasma. Newly formed vessels exhibit transendothelial leakage and the rate of 
diffusion of the tracer from the vessels is a reflection of the integrity of the microvessel wall. 
As a consequence of high angiogenic activity, high-grade tumours may have more leaky 
vessels (41). Increased vessel permeability is related to the histological grade of the glioma, 
and positive correlations between vascular parameters assessed by DCE-MRI and glioma 
aggressiveness (91, 92) and length of patient survival have been reported (92). Parametric 
maps of permeability transfer constants and blood volume may display regional differences 
in the distribution of kinetic parameters within brain tumours (91, 93, 94), and  provide 
unique insights into tumour structure, function and response to treatment. DCE-MRI is 
increasingly being used to evaluate antiangiogenic and antivascular therapy agents in early 
stage clinical trials, and guidelines to perform clinical trials effectively with DCE-MRI have 
been made (85, 86).  
Dynamic T2/T2*-weighted sequences can be designed to be sensitive to the vascular 
phase of contrast agent delivery. Signal changes reflect tissue perfusion and cerebral blood 
volume (CBV). In recent years, assessment of vascular permeability has also been achieved 
by DSC-MRI, and a positive correlation between tumour aggressiveness and vessel leakiness 
using this method have been reported (95-97). CBV obtained with DSC-MRI can be used to 
predict the histopathological grade of tumours as CBV is generally higher in high-grade 
gliomas (grade III and IV) than in grade II gliomas (95, 98, 99). DSC-MRI is mainly carried 
out by rapid T2/T2*-weighted acquisitions following the first pass of a contrast agent bolus 
through the microcirculation of the region of interest (ROI), with a typical temporal 
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resolution of 1-2 seconds. As the contrast agent follows the blood through the capillaries, it 
induces a susceptibility effect seen as signal attenuation on the T2/T2*-weighted images. To 
date, MR measurements of CBV have been evaluated for assessment of tumour 
aggressiveness, selection of biopsy location, evaluation of treatment response, and 
differentiation of recurrent tumour from treatment effects such as radiation necrosis (82).  
DWI 
DWI is sensitive to the microscopic Brownian movement of water molecules in tissues. 
Recently, DWI has gained considerable interest in the field of brain tumour imaging. Even 
though there are conflicting results regarding the clinical implications of DWI and 
quantification of the apparent diffusion coefficient (ADC), a general assumption is that 
necrotic or cystic regions of a tumour appear to be hypointense on DW images. An increased 
ADC in these regions has been reported (100-102), which may be used to differentiate brain 
tumours from brain abscesses. Lower tumoural ADC values have been linked to high-grade 
gliomas, whereas higher ADC values indicated low-grade gliomas (103, 104). Replacement 
of the normal tissue with numerous tumour cells is likely to restrict the diffusion of water, 
and a reduced ADC has been found in regions with higher cell densities (105). Also, 
components of the extracellular matrix may influence the ADC values in gliomas. A 
relationship between hyaluronan levels in the extracellular matrix and ADC values has been 
proposed for both high-grade and low-grade gliomas (106). Regions with vasogenic oedema 
have revealed increased diffusion properties compared to normal and tumour tissue (107, 
108) (Figure 5). Pre-clinical settings have also shown that diffusion MRI is an effective tool 
for evaluation of treatment response and development of drug resistance (109, 110) and may 
serve as and indicator of survival (110).  
Figure 5: ADC map of a patient with GBM 
 
  
The figure shows a parametric ADC map of the 
same patient as in Figure 3 and 4. The ADC map 
reveals an increased diffusion in the tumour 
region, indicating high degree of vasogenic 
oedema. The images are kindly provided by Turid 
Randa and Roger Barndon, Haukeland 
University Hospital. 
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1.7 Cellular MR imaging  
Cellular and molecular imaging is a relatively young but rapidly emerging field. In contrast 
to conventional diagnostic imaging, it aims at identifying cellular or molecular abnormalities 
that represent the basis of disease, rather than to image the end effect of these alternations 
(111). In addition to MRI, a broad range of imaging modalities provides possibilities to 
assess information related to physiology and pathology at a microscopic level, such as 
magnetic resonance spectroscopy (MRS), positron emission tomography (PET), single 
photon emission tomography (SPECT), optical imaging (OI), and bioluminescence imaging 
(BLI).  
The boundary between cellular and molecular imaging is not distinct and areas of 
overlap exists. In this context MRI can be classified into two categories, i.e. cellular MRI 
and molecular MRI. Cellular MRI is less specific than molecular MRI, and can be defined as 
the non-invasive and repetitive imaging of targeted cells and cellular processes in living 
organisms, whereas molecular MRI refers to imaging of subcellular components in living 
organisms (112). The development of in vivo cellular imaging by MRI allows the repeated 
measurements of specific cell loss, cell migration and regeneration (113). Until recently, in 
vivo studies of particular cell populations has been precluded by lack of appropriate 
technology as snapshot images from ex vivo histological sections have provided the only 
source to broaden our understanding of cellular dynamics. MRI-based tracking of specific 
cell populations in animals was first described in 1990 (114) and has been further developed 
in a number of laboratories  (115-122). 
1.7.1 Contrast agents for cellular labelling  
The imaging techniques used in cellular MRI do not differ from conventional MRI 
techniques as T1-weighted or T2-/T2*-weighted sequences are commonly used to visualise 
cells. It is thus the target and not necessarily the technique that differentiates between the 
two. The cells must be labelled with MR contrast agents to distinguish them from the 
surrounding tissue. As the incorporation of MR contrast agents into cells renders them 
distinct from the surrounding tissue, it allows the in vivo identification and tracking of these 
targeted cells by MRI.  Cells can either be labelled in vitro prior to transplantation, or in vivo 
by contrast agent injection into the blood stream or the ventricles of the brain (113).  
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Iron-oxide based contrast agents 
Superparamagnetic iron-oxide (SPIO) or ultrasmall SPIO (USPIO) are the most commonly 
used contrast agents for cell labelling, and the predominant effect of iron-oxide labelled cells 
is signal attenuation on T2- or T2*-weighted images. The advantage of (U)SPIO particle 
labelling is mainly due to i) the largest change in signal intensity per unit of metal, ii) iron is 
biodegradable and can therefore be re-used or recycled by cells, iii) their surface coating, 
mainly dextran, allows straightforward chemical linkage between functional groups and 
ligands, iv) they can be detected by light and electron microscopy using staining techniques 
such as Prussian Blue, and v) their magnetic properties can be changed by varying their size. 
Recently, several groups reported in vivo tracking of single cells by incorporation of 
micrometer-sized iron-oxide particles (MPIOs) (123) or SPIOs (124, 125) into cells. This 
may lead to the early detection of cancer cell migration and more detailed information about 
stem cell migration and homing. Generally, a drawback of using (U)SPIOs for cell labelling 
is the blooming susceptibility artefact that involves an area substantially larger than the 
localisation of labelled cells, due to clustering of iron-oxide particles within the endosomes 
of the cells. The “black holes” induced by iron-oxide labelled cells also may be difficult to 
differentiate from signal loss due to susceptibility artefacts or imperfect pulse sequences 
(112). Moreover, distinguishing (U)SPIO-labelled cells from haemorrhage or necrosis is 
difficult on T2-/T2*-weighted images due to similar signal characteristics and partial volume 
effects from surrounding tissue (126).  
Gd-based contrast agents 
Contrast agents based on gadolinium or manganese represent an alternative labelling 
method, as these contrast agents are predominantly positive, and signal gain is easier to 
interpret than signal loss (113). Anderson and co-workers have reported promising results by 
using gadolinium-fullerenol compounds (Gd@C82) for cellular labelling and detection with 
MRI, also at high field strengths (126). The development of bimodal and multimodal 
contrast agents may be of added value; for instance can contrast agents containing a 
fluorescent dye provide the possibility to detect labelled cells with both MRI, fluorescent 
histology, and/or optical imaging (127, 128). Gadolinium Rhodamine Dextran (GRID) is an 
example of a bimodal contrast agent with both paramagnetic and fluorescent properties 
(127). GRID consists of a dextran polymer backbone, amino-modified (CH2)4-NH2 with 
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covalently attached Gd3+ chelates and tetramethylrhodamine and with a total molecular 
weight of ~ 17 kDa (Figure 6). GRID has been used for tracking grafted NSCs in stroke 
models (122, 129). The functional status of cells can be investigated by cellular 
incorporation of responsive contrast agents that only influence the signal intensity after 
enzymatic cleavage of the Gd-compound (130). Despite the versatility of Gd-based contrast 
agents, the magnetic momentum of paramagnetic compounds is smaller than for iron-oxide 
based agents, and hence a greater number of labelled cells is normally required to induce 
signal change (131).  
Generally, for both paramagnetic and superparamagnetic compounds, the detection 
limits depend mainly on the concentration of the intracellular label and the spatial resolution 
of the MR image, which is largely determined by the external field strength. In the case of 
(U)SPIO, the detectability of labelled cells may be improved by modification of inhalation 
gases, as the intrinsic T2* effect of large vessels is reduced by increasing the oxygen content 
(132). 
Figure 6: The bimodal Gd-based contrast agent GRID (gadolinium rhodamine dextran)  
 
 
 
 
 
 
 
1.7.2 Cellular uptake 
For cellular imaging, contrast agents are generally taken up by cells through: i) 
phagocytosis, ii) receptors or receptor mediated endocytosis, or iii) pinocytosis. When cells 
are incubated for several hours with high concentrations of Gd-based agents in the growth 
The figure shows the molecular 
structure of GRID (kindly 
provided by Professor Tom 
Meade, Northwestern, Evanston, 
Il.). 
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medium, pinocytosis has shown to be an important mechanism for cellular uptake (133). 
However, cells do not readily take up large compounds, but coating of particles with contrast 
agents can significantly improve cellular uptake (134, 135). By mixing the (U)SPIO 
formulation and the transfection agent, complexes of the two are formed through 
electrostatic interactions (136). The complex is taken up by the cells through formation of 
endosomes when added into the cell culture. Among commercially available (U)SPIO 
formulations used for cell labelling are Feridex, Endorem, and Sinerem (137).   
Regardless of the labelling method or type of contrast agent used, labelling of cells 
should not impair cellular functions such as viability, proliferation, metabolism, migration 
and differentiation (113) and this issue should be thoroughly addressed prior to in vivo 
cellular imaging. Even though Gd-based contrast agents are chelated and non-toxic when 
administered, a potential biological degradation will expose the cells to toxic metals. Further 
work has to be done regarding the determination of long-term effects of cellular 
incorporation of iron-oxide- or Gd-based contrast agents (112), and the long-term stability of 
these compounds should be thoroughly investigated prior to clinical trials using cellular 
imaging with MRI.  
1.7.3 Implications of cellular MRI of the CNS using animal models  
Stem cell-based therapy is currently finding its translation from bench to bedside (138-141). 
As a part of this process, it is important to monitor the survival and differentiation of 
transplanted cells, as well as the accuracy of cell delivery. Cellular MRI is in the process of 
developing tools making this happen, and numerous studies have been performed to image 
the fate of transplanted stem cells and immune cells in different animal models. In this 
respect, prelabelling of cells with contrast agents is the most widely used method for cellular 
imaging, and enables the detection of grafted cells by MRI. The early visualisation of 
pathogenesis and evolution in an autoimmune condition, multiple sclerosis, was achieved by 
prelabelling T-lymphocytes and then tracking the grafted cells in mice by in vivo MRI (142, 
143). The capacity of magnetically labelled transplanted oligodendrocytes and their 
precursor cells to (re)myelinate axons was demonstrated by Bulte and colleagues using 
cellular MRI (116). Jendelova and co-workers visualised the fate of transplanted or i.v. 
injected  bone marrow stromal cells after inducing photochemical lesions in the cortex of the 
rat brain (144). Several research groups have tracked the migration of magnetically labelled 
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stem cells of different origin from the seeding site over corpus callosum to the damaged 
tissue in the contralateral hemisphere in rat brain with induced stroke (118, 122, 145). The 
tropism of labelled neural progenitor cells to gliomas has also been evaluated by cellular 
MRI (120), and tumour angiogenesis and neovasculature has been directly identified by 
tracking the labelled endothelial precursor cells in glioma models (115, 146). Also, Jiang and 
colleagues showed that neural progenitor cell induced angiogenesis after embolic stroke in 
the rat brain (147).  
Imaging of endogenous cells requires in vivo labelling of cells with contrast agents. 
Shapiro and co-workers tracked the migratory pathway of endogenous neural precursor cells 
in the rat brain by direct injection of MPIOs in the lateral ventricles near the subventricular 
zone (148). Visualisation of damaged and regenerating optic nerves has been achieved by in 
vivo labelling with manganese following intraocular injection of the contrast agent (149). 
1.7.4 Clinical implications of cellular MRI 
Direct imaging of pathological changes at the cellular/molecular level may provide a better 
detection of the disease which may have an impact on treatment strategies and patient care 
(111). So far, cellular MRI has mainly been used in experimental settings, but some clinical 
trials have been conducted. de Vries and co-workers demonstrated the potential of using 
cellular MRI for tracking therapeutic cells in melanoma patients as they were able to detect 
Endorem-labelled T-cells in lymph nodes (150). Zhu et al. were able to track Feridex-
labelled NSC in a patient with brain trauma (151). However, an essential prerequisite of 
cellular MRI of patients is that cellular tracking can not interfere with the routine assessment 
of the disease. It is envisioned that cellular MRI will be a valuable tool for evaluating the 
efficacy of cell-based therapy strategies in the future (113). 
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2.0 Aims of the thesis 
Based on the introduction, it is clear that there is still a lack of knowledge in understanding 
the progression and biological behaviour of glioma growth, as well as their response to new 
treatment modalities. Therefore, the main aim of this thesis was to investigate brain tumour 
phenotypes and brain tumour therapy strategies in animal models using forefront MR 
imaging techniques, novel contrast agents and advanced data analysis strategies. 
 
Paper I: To investigate brain tumour characteristics using multiparametric MR imaging and 
subsequent multiparametric data analyses to identify NG2 as a mediator of aggressive 
tumour cell behaviour in vivo. 
 
Paper II: To evaluate the potential of GRID for cell tracking with cellular MRI by 
investigating its relaxivity and its effects on labelled NSCs in vitro. 
 
Paper III: To investigate the potential of NSCs as a vehicle for targeted therapy of brain 
tumours using a rat glioma model and in vivo cellular multiparametric MRI. 
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3.0 Discussion 
In this thesis, a broad range of MR imaging techniques has been applied to assess tumour 
progression longitudinally and to evaluate cell-based treatment strategies. In vivo MR 
findings have been corroborating ex vivo histological data, which is regarded as the method 
of choice when evaluating tumour aggressiveness and tumour grading. MRI proved to be a 
valuable tool for achieving both structural and functional information and provided 
important information about the biological status of the gliomas. Also, we were able to track 
the migration of magnetically labelled NSCs from the seeding site to the glioma region. 
3.1 Experimental design 
3.1.1 Experimental glioma models 
In paper I, the U251 human glioma cell line was used. This cell line was initiated from a 
biopsy taken from a 57 year old male patient diagnosed with GBM (152). To avoid rejection 
of the grafted cells, human derived cell lines are usually xenotransplanted into immuno-
compromised mice or rats. The U251 tumour are pleomorphic, induce angiogenesis, 
necrosis, and show progressive growth when injected into congenitally athymic animals 
(152). This cell line was genetically modified to express NG2 (U251-NG2) (64). 
Xenografted U251-NG2 cells give rise to more vascularised, structurally distinct lesions in 
vivo (64). This model is therefore well suited to investigate whether the vasculature of NG2 
positive tumours was structurally and functionally distinct from the NG2 negative tumour 
vasculature. 
In paper II and III, the CNS-1 rat glioma cell line was used in both in vitro and in 
vivo assessments of the migratory potential of GRID-labelled NSCs. The CNS-1 
astrocytoma is a chemically induced tumour derived from an inbred Lewis rat that had 
received i.v. injection of N-nitroso-N-methylurea (NNU) weekly during a period of six 
months (153). The CNS-1 tumour has been characterised as an astrocytoma based on its 
immunoreactivity for glial fibrillary acidic protein (GFAP) and S100 protein. When 
implanted intracranially into rats, the histopathological characteristics of the CNS-1 tumours 
show many histopathological characteristics similar to those of human GBMs.  CNS-1 
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tumours are highly angiogenic, show perivascular infiltration, and single cell migration into 
brain parenchyma (153, 154), as well as  necrosis with palisading cells in the tumour centre 
(154). CNS-1 tumours also show extensive macrophage infiltration (155), as also seen in 
human GBMs (156). All these biological characteristics make CNS-1 tumours an attractive 
model for studying underlying mechanisms behind tumour progression, as well as novel 
treatment strategies. Also, since the CNS-1 tumours exhibited many of the same 
heterogeneous signal changes on MR images as detected in human GBMs, the model is well 
suited for evaluating the applicability of using GRID for cell tracking. 
3.1.2  Quantification of microvascular parameters 
Perfusion is central to our understanding of the tumour microenvironment, and DCE-MRI is 
one method that may provide this information. However, there are both biological and 
methodological issues that may complicate accurate measurements of microvessel 
permeability parameters. Tumour vasculature is highly disorganised, vessels are tortuous and 
dilated with uneven lumen diameters and the blood flow may be chaotic and dysfunctional. 
The vasculature in and around brain tumours exhibits a wide range of permeabilities, from 
normal capillaries with essential no BBB leakage to tumour vasculature that freely passes 
even large molecules. Thus, an important step towards measurements that are closely linked 
to the underlying pathophysiology is to choose appropriate data analysis methods. 
The enhancement kinetics of a tumour seen on T1-weighted images are dependent on 
several factors, including tissue blood flow, capillary permeability to the contrast agent, 
volume of extracellular space, inherent T1 relaxation time of the tissue, type and dose of 
contrast agent used, as well as imaging sequence and parameters (157). Another important 
issue is the potential occurrence and degree of spatial misregistation between image frames 
in the dynamic imaging time series. To reduce a potential bias, the animals were carefully 
immobilised. Thereafter post acquisition image co-registration and realignment were 
performed (using corresponding control points with a normalised cross-correlation 
technique, followed by conformal transformation from pairs of control points). The resulting 
cine loops of dynamic images were then inspected visually.  
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Objective analyses of microvascular parameters can be performed by 
semiquantitative analysis (measuring changes in signal intensity) or by fitting 
pharmacokinetic models to tissue contrast agent concentration-time curves (converting 
signal intensities to tissue concentrations). Semiquantitative parameters are relatively 
straightforward to calculate but an important limitation is that they do not accurately reflect 
the contrast agent concentration, are strongly dependent on acquisition parameters, and may 
not be physiologically based (157).  
Paper I was aimed at describing the functional status of vessels in tumours by 
quantifying microvascular parameters using two different pharmacokinetic models 
developed by Su and co-workers (19, 158, 159) and Tofts and colleagues (89, 90, 160). The 
signal intensity curve was converted to tissue concentration based on the assumption that the 
increase in T1 relaxation rate is proportional to the concentration of the tracer: 
CT = [1/T1c – 1/T10] .1/r1,  
where CT is the tissue concentration of the tracer in the tissue, T1c is the relaxation time at a 
given tracer concentration, T10 is the relaxation time in the absence of the tracer, and r1 is the 
contrast agent’s T1-relaxivity. Both models are also based on the following biological 
assumptions: i) the tracer is well mixed in the plasma, ii) there are two compartments 
available for the tracer; blood plasma and extravascular extracellular space (EES), and iii) 
flow is larger then the depletion of the tracer due to leakage (i.e. permeability-limited 
models). Also, they assume that there is a bi-directional exchange between the vessels and 
EES, where D1 and Ktrans describe vessel-tissue leakage and K2 and kep the tracer’s wash-out 
rate or rate constant from EES to blood (90, 158).  
Su's model assumes that there is a slow to intermediate water exchange between the 
vascular and extravascular compartments. Therefore, the intra- and extravascular spaces 
relax with separate time constants. This allows an estimation of the fractional blood volume, 
D0, which is related to the initial slope of the concentration-time curve (158). There may be 
some concerns regarding the validity of the analysis. First, quick leakage of the contrast 
agent into the extravascular space will lead to an over-estimation of the vascular space. 
Second, the assumption of slow water exchange is not always correct. In the case of a 
disrupted BBB, the transcapillary water exchange between intravascular and extravascular 
spaces increases (161). With an i.v. bolus injection, the longitudinal relaxation rate of water 
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protons in blood immediately increases and may also initially elevate the R1 in tissue. Tofts' 
model assumes fast water exchange between the intravascular and extravascular 
compartments. This results in a uniform T1 relaxation in the tissue as the tissue relaxes 
mono-exponentially with a relaxation rate given by the volume-weighted average of the 
compartment's relaxation rates. Thus, the total tissue concentration is estimated and the 
contribution of the intravascular tracer is neglected. However, in some cases such as brain 
tumours with increased blood volume, the intravascular tracer could contribute to a large 
portion of the observed tissue signal and give errors in the estimates of Ktrans (90).  
Based on these issues, we implemented both models to see whether our findings were 
mainly model dependent or if they could reflect genuine biological processes. When 
evaluating the suitability of the models on our data, pixel-wise numerical "goodness-of-fit" 
for the two pharmacokinetic models in different ROIs revealed that both models were well 
fitted to the time-concentration curves. However, Su's models showed a better fit at higher 
contrast agent concentrations, indicating that this model may be better in some cases (162). 
Since there was a good correlation between the permeability parameters obtained with the 
different pharmacokinetic models employed (i.e. D1 versus Ktrans, and K2 versus kep, (162)), 
we were able to confirm that our findings are based on the biological differences between the 
two glioma phenotypes. Also, estimates of the fractional blood volumes based on MRI data 
were in concordance with estimates of MVD based on histological data. However, as we 
presented our data as mean values of the total tumour region, the heterogeneity of 
microvascular permeability may be masked. Tumour heterogeneity may be better visualised 
when presenting data as the distribution of the microvascular parameters in histograms and 
as voxel-wise parametric maps. 
3.1.3 Multiparametric imaging and data analyses  
Discrimination of the boundaries between malignant and normal tissue, and the evaluation of 
cellular heterogeneity in lesions, has proven to be a limitation in conventional MRI. The use 
of multiparametric or multispectral imaging and subsequent post image acquisition 
processing techniques, such as multiparametric data analysis, may provide more accurate 
information and hence, better tumour lesion characteristics. Multiparametric data analysis 
refers to simultaneous image analysis of multiple images that provide complementary 
information about the same scene (163, 164). After co-registration of the images as 
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described in section 3.1.2, we generated colour-coded images (RGB) from T2- (red channel), 
FLAIR (green channel), and T1-weighted post-contrast (blue channel) images based on the 
signal intensities (paper I). Each of the imaging sequences produced different tissue contrast. 
Classification and estimation of tumour lesion subvolumes such as peritumoural oedema, 
solid tumour tissue, and necrosis was performed by manual delineation on RGB images. 
Three-dimensional scatter plots or feature maps derived from the multiparametric images, 
displayed the simultaneous combination of the observed signal intensities, and were used as 
a visual control for the classification of the different subvolumes. However, the manual part 
of this procedure may induce interobserver or intraobserver variability, and automated 
methods such as segmentation based on global or local thresholding, or seed growing 
methods may be preferable (165).  
In our multiparametric analysis of structural images we used three inputs (paper I), 
based on the assumption that separation of different tumour subvolumes will be improved 
using multiple imaging sequences. Because many tissues have overlapping MR signal 
intensities in a given channel, the use of three input images will increase the discrimination 
ability of different tumour subcompartments (165, 166). 
When comparing contrast enhancement patterns of differently sized contrast agents 
(paper I), two input channels were used. Regions within the tumour with signal enhancement 
with Gadomer (green channel) and/or Gd-DTPA-BMA (red channel) were compared to 
visualise the differences in vessel permeability of high- and low-molecular weight tracers, 
respectively. A potential over- or under-estimation of the areas with signal enhancement 
after Gadomer injection is possible due to partial volume effects induced by poor spatial 
resolution of the DCE-MRI sequence. However, as differences in signal enhancement 
patterns between the two contrast agents were striking, the multiparametric voxel-wise maps 
may demonstrate important underlying biological mechanisms. 
Multiparametric imaging also proved to be an important tool when evaluating tumour 
progression and cell migration of magnetically labelled stem cells in paper III. The contrast-
to-noise ratio (CNR) was estimated in specific ROIs in different imaging sequences (i.e. T2-, 
T2*-, and T1-weighted pre-contrast images) to visualise and quantify signal changes caused 
by the labelled stem cells in specific areas. Albeit we did not perform multiparametric 
analysis in terms of generating multiparametric maps, we were able to combine the 
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information obtained from the different imaging sequences, and demonstrate that changes in 
CNR on the images were most likely due the migration and homing of magnetically labelled 
cells into tumour tissue. Multiparametric imaging and subsequent CNR measurements also 
revealed signal changes due to migration of labelled cells that were not easily detected by 
the human eye. 
3.1.4 Contrast agents 
Due to their versatile properties, Gd-based contrast agents were used in all three studies. 
Post-contrast T1-weighted images after i.v. injections of Gd-DTPA-BMA (molecular weight 
= 0.58 kDa) were employed for tumour detection, delineation of the solid tumour, and 
estimation of tumour volumes in paper I and III. While low-molecular weight Gd-based 
contrast agents are effective in distinguishing defective and leaky tumour endothelium from 
the normal counterparts, they only marginally discriminate the vasculature of distinct tumour 
types (159). Gadomer was therefore used as a tracer in DCE-MRI for evaluation of the 
microvascular permeability in tumours (paper I). This contrast agent is a dendritic 
gadolinium chelate containing 24 Gd-ions with a molecular weight of 17 kDa but because of 
its globular configuration, it has an apparent molecular weight of 30-35 kDa (167). 
Microvascular permeability assays using macromolecular contrast agents correlates well 
with histologic tumour grade (18), and seem to better reveal variations in tumour 
permeability than contrast agents with lower molecular weight (19, 168). Our results (paper 
I) support that notion. Earlier detection of changes in microvascular parameters after 
treatment have also been reported using macromolecular contrast agents (19, 20, 169). 
Moreover, high-molecular weight tracers as Gadomer may be more suitable for assessment 
of microvascular parameters using permeability-limited, pharmacokinetic models since their 
transport across the tumour vessels is slower than with low-molecular weight Gd-based 
contrast agents (170). 
Cells were labelled with the bimodal contrast agent GRID to detect grafted NSCs in 
the rat brain (paper III). As Gd-based contrast agents have an effect on both T1 and T2 
relaxation rates, signal changes in both T1-weighted and T2-weighted images could be 
expected. This may be of advantage when evaluating homing of labelled cells in tumour 
regions with very heterogeneous MR signals. However, previous in vivo studies using GRID 
reported signal attenuation on T2-weighted images but no signal enhancement on T1-
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weighted images (122). This coincided with the in vitro signal intensity measurements in 
paper II. Despite relatively high T1 relaxivity of GRID at 4.7 T, no signal changes where 
detected in gels with labelled cells. This may be the result of sequestration, possible steric 
changes, and other impediments to water access and favourable motion characteristics of the 
contrast agent in the intracellular environment (126). However, the effect of intracellular 
GRID on T1-weighted images may evolve over time as higher concentrations of Gd inside 
the cells may quench the observed relaxivity (171). Despite being conditionally 
immortalised, the murine neural stem cells MHP36 may undergo 2-3 cell divisions before 
ceasing to proliferate in non-permissive conditions. This will result in a lower intracellular 
Gd-concentration over time before stabilising. Although it has been previously demonstrated 
that GRID does not leak from viable cells (119), the death of cells can result in GRID being 
present in the extracellular environment. It is therefore possible that signal increase on T1-
weighted images was partly due to GRID that has been released by the death of some NSCs. 
Although cells labelled with GRID were detected by multiparametric imaging, it would be 
beneficial if the effects on image contrast on T1-weighted images were more pronounced, 
especially in pathological processes that exhibit a heterogeneous appearance on MR images. 
It is therefore desirable to identify an agent that will exert a strong T1 effect intracellularly 
as well as a T2 effect, allowing detection of cells in disease models in which the cells need 
to be conspicuous versus the tissue, and where cell numbers of interest may be low. 
3.2 Experimental findings 
3.2.1 NG2 expression mediates an aggressive glioma phenotype 
In paper I, the effects of NG2 on tumour progression were investigated. The tumours were 
longitudinally monitored in vivo using multiparametric MRI to assess vascular permeability, 
solid tumour volumes, vasogenic oedema and necrosis. This was done to determine whether 
NG2 expressing tumours showed different growth characteristics compared to its U251-WT 
(WT) wild type counterparts. The microvasculature of U251-NG2 tumours exhibited 
increased vessel leakiness expressed by higher D1- and Ktrans - values compared to WT 
tumours. Also, estimates of D0 as a measure of fractional blood volume revealed that NG2 
expressing tumours had a larger blood supply than WT tumours. Immunohistochemistry and 
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electron-microscopy showed that the U251-NG2 tumours had a higher microvascular density 
(MVD) with vessels that displayed larger gaps between endothelial cells. Thus, tumour cells 
can regulate both the function and structure of the host derived tumour vasculature through 
NG2 expression, suggesting a role of NG2 in the cross-talk between tumour-host 
compartments.  
NG2 expressing tumours also exhibited different features compared to WT tumours 
regarding tumour growth, vasogenic oedema and necrosis. U251-NG2 tumours rapidly 
developed with an accelerated expansion of the solid tumour mass, reflected by a shorter 
tumour volume doubling time than WT tumours. Development of MR visible necrotic foci 
correlated well with shorter survival of the U251-NG2 animals compared to the WT 
recipients. Our results showed that U251-NG2 tumour bearing animals developed vasogenic 
oedema in the surrounding brain parenchyma to a larger extent than WT animals, indicating 
that NG2 may play a role in the disruption of the BBB. This is an important finding as 
mechanisms of oedema formation in brain tumours are linked to tumourigenesis, and 
peritumoural oedema is a significant source of morbidity and mortality (172).  
3.2.2 Signal enhancement with differently sized contrast agents 
Qualitative analysis of the contrast enhancement pattern using different contrast agents 
revealed spatial heterogeneity in uptake depending on their molecular size (paper I). There is 
a spatial heterogeneity in blood supply of the solid tumour mass. Coupled with increased 
interstitial pressure centrally in the tumour, which lowers the extravasation of fluid and 
blood-borne molecules especially for macromolecular substances (173), it may explain the 
different contrast enhancement pattern between Gd-DTPA-BMA and Gadomer in these 
regions. Contrast enhancement with Gd-DTPA-BMA revealed a more homogeneous pattern, 
most likely due to a more rapid diffusion of smaller particles from the well-perfused 
peripheral region towards low-perfused central regions. These differences in the spatial 
tissue distribution of Gd-DTPA-BMA and Gadomer may indicate distinctive roles of the 
contrast agent in characterisation and estimation of tumour microvascular function. 
Treatment strategies based on blood-borne molecules are dependent on microvascular 
perfusion, permeability, and finally, the diffusion of the substance through the interstitium 
(174). Knowledge about spatial distribution of macromolecular particles is important for 
treatment planning and for the prediction of treatment response to blood-borne therapeutic 
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agents. The pattern of contrast enhancement in solid tumour tissue after administration of 
Gadomer may indicate the spatial distribution of therapeutic agents, and if so, it can be a 
valuable tool in treatment planning of blood-borne substances. Our results also indicate that 
Gd-DTPA-BMA, most likely due to higher permeability and faster diffusion, is better for the 
delineation and visualisation of viable tumour tissue. Qualitative analysis of contrast 
enhancement pattern also revealed pronounced differences in the uptake of different contrast 
agents in the WT compared to the U251-NG2 tumours. This may be explained by a lower 
permeability of large molecules in less aggressive tumours.  
3.2.3 GRID visualises cells both in vitro, in vivo and ex vivo 
The bimodal properties of GRID both allowed visualisation of labelled cells with 
fluorescence microscopy and MRI, as well as investigations of the migratory potential of 
labelled NSCs in vivo and ex vivo (paper III). In vitro identification of GRID-labelled cells 
in gels was also possible with MRI (paper II). The cells were fully saturated with GRID 
(100% labelling efficacy) after 16 hours of incubation as detected with both relative 
fluorescence measurements and ICP-MS. This is important when evaluating the fate and 
potential effects of the grafted labelled cells in vivo as the unlabelled fraction of cells will 
not induce signal changes and can therefore not be detected by cellular MRI. A minimum 
incubation time is desirable, and we found that 16 hours of incubation is acceptable. In 
comparison, cell labelling with the iron-oxide based contrast agent Endorem required up to 
72 hours of incubation to obtain sufficient uptake of the contrast agent (144). Fluorescent 
micrographs demonstrated that intracellular GRID was located in the cytoplasm of MHP36 
cells, and that cells could be detected up to one week after labelling in both permissive and 
non-permissive conditions (paper II). In vivo experiments showed that signal changes 
induced by labelled cells were detected by MRI 9 days after grafting, indicating good 
cellular preservation of the contrast agent (paper III). These results are consistent with 
previous findings (122, 129). GRID-labelled cells induced signal attenuation on T2-weighted 
images and a modest signal enhancement on T1-weighted images, which were quantified by 
CNR measurements (paper III).  
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3.2.4 GRID does not impair cellular functions of labelled cells in vitro 
Attractive properties of NSCs in stem cell-based therapies are their potential to generate a 
more differentiated progeny, capacity of self-renewal, and their motility as a response to 
pathological cues. These issues were addressed in paper II. MHP36 cells showed preserved 
differentiation after labelling with GRID as these cells developed into oligodendrocytes, 
astrocytes and neurons under appropriate conditions. Compared to PKH26 labelled NSCs, 
the migratory potential of GRID-labelled NSCs were not affected, indicating that labelled 
cells keep their ability to respond to pathological processes.  
The toxicity of GRID was also investigated in terms of viability, proliferation, and 
metabolism. A significantly increased level of reactive oxygen species was seen in labelled 
cells but this was not reflected in s decrease in viability. However, proliferation of GRID-
labelled NSCs dependent on the length of incubation, and cell counting revealed significant 
decrease in proliferation after 16 and 24 hours of labelling. Confirming these results, a 3-
(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay, showed a 
reduction of mitochondrial activity after 24 hours of labelling. Decreased MTT ratio of 
labelled cells with Gd-based agents compared with unlabelled cells has also been observed 
by others (126). Decreased proliferation/metabolism in cells after labelling of Gd-based 
agents may be due to possible interactions of released Gd-ions with calcium channels and an 
interference with electron transport and mitochondrial function (175). However, high 
viability of labelled cells indicates that Gd-ions are not released in cells, and that the reduced 
mitochondrial activity is induced by other properties of GRID. The biological impact of the 
reduction in mitochondrial activity may not be of biological significance as cellular 
functions of labelled cells were not impaired.  Based on this, GRID may be regarded as a 
safe and reliable method for labelling cells in animal models. However, potential long-term 
toxicity and the in vivo cellular effects of GRID and other Gd-based contrast agents should 
be thoroughly investigated before employing this contrast agent as a cellular tracer in 
humans. 
3.2.5 NSCs as a therapeutic modality in brain tumours 
GRID-labelled NSCs exhibited transhemispheric migration from the seeding site to the 
tumour regions in rat brains as demonstrated both with in vivo serial cellular MRI and with 
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ex vivo histological assessments (paper III). This confirms previous observations showing 
that NSCs are attracted by signals derived from the tumour (47, 55). NSCs respond to three 
physiological processes that are common to many brain pathologies: inflammation, reactive 
astrocytosis and angiogenesis (53). A potential intrinsic tumour-inhibitory effect of grafted 
NSCs was observed, reflected by a decreased tumour doubling time and reduced vasogenic 
oedema in NSCs treated animals. The exact molecular mechanism for this intrinsic effect of 
NSCs is not known but our findings confirm previous reports (48, 59). Cytolytic viruses and 
genes coding for anti-tumor cytokines, pro-drug converting enzymes, and various 
neurotrophic factors have all been engineered into engraftable NSCs for targeted delivery to 
tumours (140). However, genetically modified, transplanted NSCs may persist in brain well 
after their therapeutic action and continued expression of therapeutic molecules may show 
negative effects on normal neighbouring tissues.  
3.3 Concluding remarks 
The recognition of NG2 as a progenitor/stem cell marker (69, 176) and its role in tumour 
progression, illustrates the dual role of such immature cells in healthy and diseased CNS. 
This thesis integrated both the pathological and the therapeutic effects of such cells in 
gliomas. 
Multiparametric MR imaging and data analyses revealed that the NG2 expressing 
tumours have an increased vascular permeability and blood fraction, more prominent 
vasogenic oedema and necrosis, as well as an accelerated tumour growth. Based on these 
findings, we postulate that NG2 expression mediates a more aggressive glioma phenotype. 
Its involvement in multiple facets of tumour cell biology, underlines its potential as a 
possible therapeutic target. 
MRI proved to be an important tool in evaluating NSCs as a vehicle to target the 
tumour. Cellular MRI visualised the migration and homing of GRID-labelled NSC to brain 
tumours. The Gd-based bimodal contrast agent GRID proved to be an efficient method to 
label cells and allowed the detection of grafted cells by MRI both in vitro and in vivo. GRID 
did not change the biological behaviour of labelled cells in vitro underlining the attractive 
role of NSCs as therapeutic vehicles. 
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4.0 Future prospects 
The potential use of NSCs in brain tumour therapy will most likely represent a 
supplementary treatment approach that should not substitute conventional treatment 
strategies (177). However, the unique ability of NSCs to "home in" on tumour cells followed 
by the delivery of a desired gene product makes NSCs a very promising agent in brain 
tumour therapy. An interesting strategy is to use genetically engineered NSCs to target 
BTSCs which are believed to initiate tumourigenesis and maintain tumour growth. Normal 
stem cells share many properties with cancer stem cells, most notably the trait of self-
renewal, and the question whether BTSCs are diseased NSCs has been raised (178, 179). 
Thus, it will be imperative to secure that grafted cells can not be transformed into tumour-
initiating cells. Most stem cell-based gene therapy concepts are still in the preclinical 
evaluation phase and will have to pass significant hurdles to become viable therapeutic 
options. In this context it is important to assess potential hazards and outline safety measures 
related to cell therapy approaches. 
  In vivo evaluation of the efficacy of stem cell-based therapy is possible using cellular 
MRI and further developments of contrast agents for cellular labelling and FDA-approval of 
these, will emphasise the role of cellular MRI. Functional MRI will most likely be an 
integrated part in monitoring tumour progression and treatment response. More extensive 
use of (semi)automated pattern recognition techniques for multispectral data analyses, where 
conventional images are combined or replaced with pharmacokinetic maps and/or ADC 
maps to generate multidimensional feature maps, will also provide valuable information.  
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